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Introduction {#sec001}
============

Ataxia telangiectasia mutated (ATM) is a protein kinase belonging to the superfamily of phosphatidylinositol 3-kinase related kinases (PIKKs), is well known for its role in activation of DNA damage response pathways following DNA double strand breaks (DSBs) \[[@pone.0134678.ref001]--[@pone.0134678.ref004]\]. ATM reportedly responds to DSBs, by autophosphorylation at Ser-1981, leading to dissociation of inactive multimeric ATM to form active monomers, which allows it to associate with MRN complexes (MRE 11, RAD50 and NBS1 complex) and phosphorylate its downstream regulators of DNA repair such as histone H2AX, MDC1, 53BP1 and BRCA1 \[[@pone.0134678.ref001]--[@pone.0134678.ref003]\]. In addition to canonical responses to DSBs, ATM has also been shown to regulate the repair of single strand breaks (SSBs) and nucleotide excision repair \[[@pone.0134678.ref005]--[@pone.0134678.ref009]\].

Functional loss of ATM, caused by hereditary mutations in the gene predisposes individuals to Ataxia Telangiectasia (A-T); an autosomal recessive disorder characterized by neurodegeneration, immune deficiency, hypersensitivity to ionizing radiation and increased frequency of cancers \[[@pone.0134678.ref010]--[@pone.0134678.ref011]\]. Mutations in the ATM gene have been reported in several types of cancers including familial pancreatic, breast, ovarian, colorectal, haematologic cancers and in lung cancers illustrating the significance of ATM in cancer pathogenesis \[[@pone.0134678.ref012]--[@pone.0134678.ref017]\]. Studies in tumor samples from pancreatic, breast and gastric cancer patients revealed a correlation between loss of ATM expression, disease progression and poor prognosis, indicating its tumor suppressing nature \[[@pone.0134678.ref018]--[@pone.0134678.ref021]\]. Interestingly, tissue microarray analysis of samples from endometrial cancer patients showed a correlation between ATM positivity, disease progression and increased probability of recurrence, pointing towards the oncogenic nature of ATM \[[@pone.0134678.ref022]\]. Similarly, analysis of phosphorylated ATM (p-ATM) expression in cervical cancer patients revealed an association between high nuclear p-ATM expression in tumor samples and locoregional disease free survival, as well as poor response to chemotherapy \[[@pone.0134678.ref023]\].

ATM is known to activate oncogenic signalling cascades with its targets including kinases like Akt/PKB, and transcription factors like Nuclear Factor Kappa Beta (NFκB), and Hypoxia Inducible Factor-1α (HIF1α) \[[@pone.0134678.ref001]\]. In line with the results from endometrial cancer patients, analysis of ATM expression (mRNA and protein) in melanoma reported an upregulation of ATM in nodular malignant melanoma samples \[[@pone.0134678.ref024]\]. However, the sample size of the study was small with less than twenty five cases and the study was unable to clarify the association between ATM expression and prognosis. Moreover, the study did not analyze p-ATM expression in patients. Considering the significance of phosphorylation in monomerization and activation of ATM, there is a need for a clear analysis on the correlation between p-ATM expression and melanoma patient survival \[[@pone.0134678.ref025]--[@pone.0134678.ref031]\].

ATM is a large protein with molecular size of approximately 350 kD, and contains PI3K-like, FAT and FATC domains towards the c-terminal \[[@pone.0134678.ref001]--[@pone.0134678.ref002], [@pone.0134678.ref032]\]. Several sites of phosphorylation on ATM have been identified, including ser-367, ser-784, ser-1403, ser-1893, ser-1981, ser-2996, & Lys-3016 (acetylation), and reported to regulate the activity of ATM \[[@pone.0134678.ref001]\]. Among them phosphorylation at ser-1981 is most commonly studied and also reported to be involved in oxidative stress induced autophosphorylation \[[@pone.0134678.ref033]\]. Since, UV-induced pyramidine dimers, 6--4 photo products as well as 8-oxoguanine lesions on DNA are considered as the main initiating factors of melanoma, and ser-1981 phosphorylated ATM is considered to be involved in the subsequent repair of DNA, we asked if ser-1981 phosphorylation of ATM is associated with melanoma progression and prognosis \[[@pone.0134678.ref001], [@pone.0134678.ref005]--[@pone.0134678.ref009], [@pone.0134678.ref034]\]. Using tissue samples collected from melanoma patients, we analyzed phospho-ATM (ser-1981) expression in melanoma patients and studied the correlation with disease progression and patient survival.

Methods {#sec002}
=======

Ethics Statement {#sec003}
----------------

The use of human skin tissues and the waiver of patient consent in this study were approved by the Clinical Research Ethics Board of the University of British Columbia \[[@pone.0134678.ref027]\]. Patient information was anonymized and de-identified prior to analysis. The study was conducted according to the principles expressed in the Declaration of Helsinki.

Patient specimens and tissue microarray construction {#sec004}
----------------------------------------------------

The collection of patient specimens and the construction of the tissue microarray (TMA) have been previously described \[[@pone.0134678.ref035]\]. We used patient data collected between 1990 and 2009. Of the 748 patients specimens collected, 425 biopsies including 366 melanoma and 59 cases of nevi (27 normal nevi and 32 dysplastic nevi) could be evaluated for p-ATM staining in this study, due to loss of biopsy cores or insufficient tumor cells present in the cores. The criteria for patient exclusion and inclusion and the demographic characteristics of melanoma patients are detailed in [S1 Table](#pone.0134678.s004){ref-type="supplementary-material"}. All specimens were obtained from the archives of the Department of Pathology, Vancouver General Hospital.

The most representative tumor area in each biopsy was carefully selected and marked on the hematoxylin and eosin stained slides and the TMAs were assembled using a tissue-array instrument (Beecher Instruments, Silver Spring, MD). Tissue cores of 0.6-mm thickness were taken in duplicate from each biopsy. Using a Leica microtome, multiple 4 μM sections were cut and transferred to adhesive-coated slides using regular histological procedures. Tissue samples from melanoma and benign nevus were built into each TMA slide as positive and negative controls. One section from each TMA was routinely stained with hematoxylin and eosin whereas the remaining sections were stored at room temperature for subsequent immunohistochemical staining.

Immunohistochemistry {#sec005}
--------------------

Tissue microarray (TMA) slides were dewaxed at 55°C for 20 min followed by three 5 min washes with xylene. The tissues were then rehydrated by washing the slides for 5 min each with 100%, 95%, 80% ethanol and finally with distilled water. The slides were heated to 95°C for 30 min in 10 mmol/L sodium citrate (pH 6.0) for antigen retrieval and then treated with 3% hydrogen peroxide for 1 hour to block endogenous peroxidase activity. After blocking the slides with the universal blocking serum (Dako Diagnostics, Carpinteria, CA, USA), the sections were incubated overnight with mouse anti-p-ATM (ser 1981) antibody (1:50 dilution; Biolegend, USA) at 4°C. The sections were incubated for 30 min with a biotin-labelled secondary antibody and then with streptavidin-peroxidase (Dako Diagnostics). The labelling was developed by treatment with 3,3'-diamino-benzidine substrate (Vector Laboratories, Burlington, Ontario, Canada) and with hematoxylin to counter-stain the nuclei. Negative controls were done by omitting the p-ATM antibody during the primary antibody incubation.

Evaluation of immunostaining {#sec006}
----------------------------

The evaluation of p-ATM staining was done blindly by microscopic examination of the tissue sections by one dermatopathologist and two other observers simultaneously, using a multiple viewing microscope and a consensus was reached for the score of each core. p-ATM staining intensity was scored as 0+, 1+, 2+, 3+ whereas the percentage of p-ATM positive cells was scored as 1 (1--25%), 2 (26--50%), 3 (51--75%) and 4 (76--100%). In cases of score discrepancy between duplicated cores, the higher score from the two tissue cores was taken as the final score. The product of intensity and percentage was taken as the immunoreactive score (IRS) \[[@pone.0134678.ref036]\]. Based on the IRS, p-ATM staining in the tissue sections was categorized as negative (IRS 0), weak (IRS 1--4), moderate (IRS 6--8), or strong (IRS 9--12). The optimum cut-off values for the IRS were derived based on the IRS pattern in nevi and melanoma. The cut-off points were additionally confirmed using the X-tile software (Yale University) \[[@pone.0134678.ref037]\].

Statistical analysis {#sec007}
--------------------

Correlation between p-ATM and clinicopathologic parameters was evaluated by Chi-square test among patient subgroups. Survival time was calculated from the date of melanoma diagnosis to the date of death or last follow-up. The association between p-ATM expression and patient survival (overall and disease-specific survival) was evaluated by Kaplan-Meier analysis and log-rank test. Additionally, univariate and multivariate Cox proportional hazards regression models were preformed to estimate the crude hazard ratios (HRs) or adjusted HRs and their 95% confidential intervals (CIs). *P*-value \<.05 was considered as statistically significant. All the statistical analyses were performed using SPSS version 16.0 (SPSS Inc, Chicago, IL) software.

Results {#sec008}
=======

Increase in as well as loss of p-ATM expression in the nucleus is associated with melanoma progression {#sec009}
------------------------------------------------------------------------------------------------------

As seen in [Fig 1](#pone.0134678.g001){ref-type="fig"} and [S1 Fig](#pone.0134678.s001){ref-type="supplementary-material"}, p-ATM expression was mainly seen in the nucleus and therefore we evaluated the staining in the nuclei of the patient biopsies. IRS scores for the p-ATM expression in the normal nevi were in between 1 & 8 with none of the cores achieving a score of either 0 or 9 to 12, whereas, 12.5% cases of dysplastic nevi samples were scored as 'negative' (0) and 6.25% of cases received an IRS score of 9 to 12. The biopsies scored as negative increased to nearly 15% in primary melanoma cases and to 20.6% in metastatic melanoma cases. Similarly, the percentage of cases receiving scores \>9, was increased to 11.7% in primary melanoma and 19.1% in metastatic melanoma. Therefore based on the IRS scoring patterns, we classified p-ATM expression as negative (IRS-0), weak to moderate (IRS 1--8), and strong (IRS 9--12), and analyzed the p-ATM expression in the patient biopsies using chi-square analysis.

![pATM expression in nuclei of melanoma samples.\
(A, B) Representative images of normal nevi (NN) and (C, D) dysplastic nevi (DN) with strong nuclear staining; (E-H) primary melanoma (PM) with negative (IRS-0, E & F) and strong (IRS 9--12, G & H) nuclear staining; (I-L) metastatic melanoma (MM) with negative (I & J) and strong (K & L) nuclear p-ATM staining.](pone.0134678.g001){#pone.0134678.g001}

As shown in [Fig 2A](#pone.0134678.g002){ref-type="fig"}, cases of both negative and strong p-ATM expressions were increased from normal nevi to dysplastic nevi but the difference did not reach statistical significance (p = 0.0597) probably due to the small sample number. There also seemed to be a marginal, but not statistically significant, increase in the percentage of negative and strong p-ATM expressions from dysplastic nevi to primary melanoma (p = 0.592). The increase in negative and strong p-ATM expressions was obvious and statistically significant (p = 0.025) from primary melanoma to metastatic melanoma. In order to verify the association between p-ATM expression and melanoma progression, we divided the cases based on AJCC stage and analyzed the correlation between p-ATM and AJCC stage. As seen in [Fig 2B](#pone.0134678.g002){ref-type="fig"}, percentage of patients with negative p-ATM expression appeared to increase from stage I to stage III and then decreased from stage III to stage IV, though the differences between melanoma stages were not statistically significant. In contrast, there was no clear difference in strong p-ATM expression between AJCC stages I through III. Percentage of patients with strong p-ATM expression tended to increase from AJCC stage III to stage IV, but the difference was not statistically significant ([Fig 2B](#pone.0134678.g002){ref-type="fig"}).

![Correlation between pATM expression and melanoma progression.\
(A) Percentage of negative (IRS 0) and strong pATM (IRS 9--12) staining in nuclei is significantly increased from normal and dysplastic nevi to melanoma by χ^2^ test.(B) Loss of pATM expression as well as increase in pATM expression in the nucleus is significantly associated with melanoma progression by χ^2^ test. (C) Loss of pATM expression as well as increase in pATM expression in the nucleus is significantly associated with tumor thickness by χ^2^ test.](pone.0134678.g002){#pone.0134678.g002}

p-ATM expression and clinicopathologic characteristics {#sec010}
------------------------------------------------------

To further test if loss or increase of p-ATM expression was related to increase in tumor thickness, we classified our database on the basis of tumor thickness ≤ 2 mm or \> 2 mm and analyzed the correlation. Chi square test analysis of the data revealed that biopsies from patients with larger tumors (\> 2 mm) had significantly higher incidence of negative or strong p-ATM staining (p = 0.009, [Fig 2C](#pone.0134678.g002){ref-type="fig"}, [Table 1](#pone.0134678.t001){ref-type="table"}). We continued with the analysis by dividing the data based on other clinicopathologic characteristics such as ulceration status, sun exposure and tumor subtype. We did not find any correlation between p-ATM expression and the rest of the demographic and clinicopathologic characteristics ([Table 1](#pone.0134678.t001){ref-type="table"}).

10.1371/journal.pone.0134678.t001

###### p-ATM staining and clinicopathological characteristics of 366 melanoma patients.

![](pone.0134678.t001){#pone.0134678.t001g}

  Variables                  Nuclear p-ATM                              
  -------------------------- --------------- ------------- ------------ -------
  **All Melanoma**                                                      
  Age                                                                   
   ≤ 60                      31 (16.4%)      130 (68.8%)   28 (14.8%)   0.951
   \> 60                     31 17.5%)       121 (68.4%)   25 (14.1%)   
  Gender                                                                
   Male                      35 (16.0%)      147 (67.1%)   37 (16.9%)   0.264
   Female                    27 (18.4%)      104 (70.7%)   16 (10.9%)   
  AJCC stage                                                            
   I                         9 (8.8%)        84 (82.4%)    9 (8.8%)     0.004
   II                        25 (19.5%)      85 (66.4%)    18 (14.1%)   
   III                       13 (23.6%)      36 (65.5%)    6 (10.9%)    
   IV                        15 (18.5%)      46 (56.8%)    20 (24.7%)   
  Site                                                                  
   Sun Protected             43 (39.5%)      194 (60.5%)   44 (60.5%)   0.211
   Sun Exposed               19 (44.1%)      57 (55.9%)    9 (55.9%)    
  **Primary Melanoma**                                                  
  Age                                                                   
   ≤ 60                      15 (13.6%)      82 (74.5%)    13 (11.8%)   0.895
   \> 60                     19 (15.8%)      87 (72.5%)    14 (11.7%)   
  Gender                                                                
   Male                      18 (15.5%)      92 (74.8%)    17 (9.7%)    0.681
   Female                    16 (14.2%)      77 (72.4%)    10 (13.4%)   
  Tumor Thickness                                                       
   ≤ 2                       11 (9.6%)       94 (82.5%)    9 (7.9%)     0.009
   \> 2                      23 (19.8%)      75 (64.7%)    18 (15.5%)   
  Ulceration                                                            
   Absent                    22 (12.4%)      136 (76.8%)   19 (10.7%)   0.094
   Present                   12 (22.6%)      33 (62.3%)    8 (15.1%)    
  Subtype                                                               
   Acrolentigous             3(37.5%)        4 (50.0%)     1 (12.5%)    0.308
   Lentigous                 4 (11.8%)       26 (76.4%)    4 (11.8%)    
   Nodular                   7 (15.6%)       30 (66.7%)    8 (17.7%)    
   Spindle cell              3(30.0%)        7 (70.0%)     0 (0.0%)     
   Superficially spreading   8 (10.3%)       64 (82.1%)    6 (7.6%)     
   Unspecified               9 (16.4%)       38 (69.1%)    8 (14.5%)    
  **Metastatic Melanoma**                                               
  Age                                                                   
   ≤ 60                      16 (49.4%)      48 (50.6%)    15 (50.6%)   0.990
   \> 60                     12 (43.5%)      34 (56.5%)    11 (56.5%)   
  Gender                                                                
   Male                      17 (18.5%)      55 (59.8%)    20 (21.7%)   0.438
   Female                    11 (25.0%)      27 (61.4%)    6 (13.6%)    

Sun-protected sites: trunk, arm, leg and feet; Sun-exposed sites: head and neck.

\*- χ^2^ test.

DNA alkylating agents like dacarbazine and temozolomide are used in melanoma treatment \[[@pone.0134678.ref038]--[@pone.0134678.ref039]\]. DNA damage is known to phosphorylate ATM at serine-1981 and activate the kinase, so we explored p-ATM expression in patients treated with DNA damaging agents \[[@pone.0134678.ref001], [@pone.0134678.ref003], [@pone.0134678.ref040]\]. Based on the chemotherapeutic treatment information available in our database, we pooled 21 patients who were administered DNA damaging agents and analyzed p-ATM expression in them. As seen in [S2 Fig](#pone.0134678.s002){ref-type="supplementary-material"}, negative p-ATM expression appeared to be more frequent in patients treated with DNA damaging agents, but the correlation was not statistically significant (p = 0.328). In vitro studies attempting to sensitize melanoma cells to radiation and/or chemotherapy by inhibition of ATM demonstrated conflicting results. While ATM inhibition was not sufficient to sensitize melanoma cells to ionizing radiation, cells lacking ATM activity were found to be sensitive to temozolamide treatment \[[@pone.0134678.ref041]--[@pone.0134678.ref043]\]. We therefore analyzed the information from DNA damaging agents administered patients to check if the p-ATM expression correlated with treatment resistance. Interestingly, strong as well as negative p-ATM expression was found to be significantly associated with resistance to chemotherapy in melanoma patients ([S3 Fig](#pone.0134678.s003){ref-type="supplementary-material"}, p = 0.0194).

Nuclear p-ATM expression and 5-year survival {#sec011}
--------------------------------------------

We then asked if the loss of or gain in p-ATM expression was associated with 5-year survival of melanoma patients. Kaplan-Meier analysis of patient survival revealed that patients with weak to moderate expression of p-ATM had significantly better overall (p = 0.04) and disease specific (p = 0.006) survival compared to patients with negative or strong p-ATM expression ([Fig 3A and 3B](#pone.0134678.g003){ref-type="fig"}). Of the three groups, patients with strong p-ATM expression had the worst prognosis; the prognosis of patients whose tissue samples were negative for p-ATM was comparatively better and the survival curve was found to be closer to the weak to moderate expression group ([Fig 3A and 3B](#pone.0134678.g003){ref-type="fig"}). We then combined the patients with negative and weak to moderate expression into one group and compared their survival with patients with strong expression only. As seen in [Fig 3C and 3D](#pone.0134678.g003){ref-type="fig"}, strong p-ATM was significantly associated with worse overall (p = 0.022) and disease specific (p = 0.003) survival. We then confirmed the association between p-ATM and patient survival, using univariate Cox regression analysis and found that patients with strong p-ATM expression had significantly worse survival compared to patients with negative to moderate expression of p-ATM ([S2 Table](#pone.0134678.s005){ref-type="supplementary-material"}).

![pATM expression and 5-year patient survival.\
Kaplan-Meier survival analyses of correlation between pATM expression and 5-year overall (left panels) and disease-specific (right panels) survival of melanoma patients classified as negative (Neg), weak-to-moderate (Weak-Mod) & strong (A and B), and as negative-to-moderate (Neg-Mod) & strong (C and D).](pone.0134678.g003){#pone.0134678.g003}

Nuclear p-ATM expression and 10-year survival {#sec012}
---------------------------------------------

Next we analyzed the patient data where information on 10-year survival was available, to check if p-ATM had a similar association with 10-year patient survival. As seen with 5-year survival, patients with weak to moderate expression of p-ATM had better overall (p = 0.002) and disease specific (p = 0.006) 10-year survival compared to patients with strong p-ATM expression ([Fig 4A and 4B](#pone.0134678.g004){ref-type="fig"}). However, patients with negative p-ATM expression also had comparatively worse survival and its representative curve was found to almost overlap with that of the strong p-ATM expression ([Fig 4A and 4B](#pone.0134678.g004){ref-type="fig"}). When we combined the patients negative and weak to moderate p-ATM expression and compared the survival with patients with strong expression, the difference between the groups was slightly decreased as seen by increase in p-values. Strong p-ATM expression was found to be significantly associated with disease specific 10-year survival ([Fig 4C and 4D](#pone.0134678.g004){ref-type="fig"}). Similar results were obtained by univariate Cox regression analysis of the data as seen by significantly worse disease specific survival of patients with strong p-ATM expression compared to patients with negative to moderate expression of p-ATM ([S2 Table](#pone.0134678.s005){ref-type="supplementary-material"}).

![pATM expression and 10-year patient survival.\
Kaplan-Meier survival analyses of correlation between pATM expression and 10-year overall (left panels) and disease-specific (right panels) survival of melanoma patients classified as negative (Neg), weak-to-moderate (Weak-Mod) & strong (A and B), and as negative-to-moderate (Neg-Mod) & strong (C and D).](pone.0134678.g004){#pone.0134678.g004}

p-ATM expression is an independent prognostic factor for 5-year survival {#sec013}
------------------------------------------------------------------------

Next we tested the prognostic significance of p-ATM expression by studying its ability to independently predict patient survival, using multivariate Cox regression analysis. We used p-ATM, age, AJCC stage and gender as a variables and analyzed the survival of the patients. p-ATM was categorized as negative to moderate vs strong, age as ≤ 60 vs \> 60, AJCC as stages I & II vs stages III & IV, and gender as male vs female. As illustrated in [Table 2](#pone.0134678.t002){ref-type="table"}, p-ATM was found to be significantly associated with 5-year survival, but not with 10-year survival of patients.

10.1371/journal.pone.0134678.t002

###### Multivariate Cox regression analysis of overall and disease-specific survival in melanoma patients.

![](pone.0134678.t002){#pone.0134678.t002g}

  Variables[\*](#t002fn001){ref-type="table-fn"}   Overall Survival   Disease-specific Survival                                                                         
  ------------------------------------------------ ------------------ --------------------------- ------------------- ------------- ------- ------- ------------------- -------------
  **5-year**                                                                                                                                                            
  pATM                                             0.362              0.196                       1.44 (0.98--2.11)   0.065         0.462   0.199   1.59 (1.07--2.34)   0.020
  AJCC                                             1.313              0.156                       3.72 (2.74--5.04)   3.4x10^-17^   1.504   0.167   4.50 (3.24--6.25)   2.5x10^-19^
  Gender                                           0.286              0.157                       1.33 (0.98--1.81)   0.069         0.279   0.166   1.32 (0.95--1.83)   0.093
  Age                                              0.356              0.151                       1.43 (1.06--1.92)   0.018         0.265   0.159   1.30 (0.95--1.78)   0.095
  **10-year**                                                                                                                                                           
  pATM                                             0.314              0.182                       1.37 (0.96--1.96)   0.085         0.370   0.192   1.45 (0.99--2.11)   0.054
  AJCC                                             0.989              0.143                       2.69 (2.03--3.56)   4.8x10^-12^   1.228   0.156   3.41 (2.51--4.64)   4.3x10^-15^
  Gender                                           0.194              0.147                       1.21 (0.91--1.62)   0.188         0.263   0.159   1.30 (0.95--1.78)   0.097
  Age                                              0.457              0.141                       1.58 (1.20--2.08)   0.001         0.311   0.152   1.37 (1.01--1.84)   0.040

\*Coding of variables: Age was coded as 1 ((60 years), and 2 (\>60 years). Gender was coded as 1 (male) and 2 (female). pATM expression was coded as 1 (neg-to-moderate) and 2 (strong). AJCC staging was coded as 1 (stages I & II), and 2 (stages III & IV).

^†^ ß: regression coefficient.

Abbreviations: SE, standard error of ß; HR, hazard ratio; CI, confidence interval.

Discussion {#sec014}
==========

Melanoma is one of the most commonly diagnosed cancers in fair skinned populations as shown by the recent report from the USA ranking it as the fifth most common cancer in men and seventh most common cancer in women \[[@pone.0134678.ref044]\]. Patients with advanced stages of melanoma have a very low survival rate (15%) and an overall survival duration between 8 to 18 months \[[@pone.0134678.ref044]\]. There are only a few treatment options available for metastatic melanoma due to its resistance to conventional chemo and radiotherapy \[[@pone.0134678.ref038]--[@pone.0134678.ref039]\]. The success of available treatment options is also limited with effectiveness restricted to a subset of patients, development of lethal resistance, or only a small increase in median survival time \[[@pone.0134678.ref038]--[@pone.0134678.ref039]\]. Consequently, the search for alternative drugs is ongoing.

Among the various origins of cancer, genomic instability is recognized as one of the major causes and UV radiation, a well-known genotoxic agent, is considered as one of the leading causes of melanoma \[[@pone.0134678.ref034], [@pone.0134678.ref045]\]. Previous studies identified that expression of several proteins involved in DNA repair were decreased or lost in melanoma patients, and that the loss of expression significantly correlated with poor patient survival \[[@pone.0134678.ref025]--[@pone.0134678.ref028], [@pone.0134678.ref031]\]. Our results here are partly in line with the previous data suggesting that a loss of mechanisms maintaining genomic integrity could be one of the critical events in melanoma pathogenesis.

The significance of ATM in cancer progression and patient prognosis has been shown in studies on tissue samples from gastric, pancreatic, bladder and endometrial cancers \[[@pone.0134678.ref019]--[@pone.0134678.ref020], [@pone.0134678.ref022], [@pone.0134678.ref046]--[@pone.0134678.ref048]\]. Previous studies on nodular metastatic melanoma samples showed an upregulation of ATM at both transcript and protein levels \[[@pone.0134678.ref024]\]. The sample size in that study was relatively low and the study did not report any association between ATM expression and patient survival. The study also did not analyze p-ATM expression in melanoma patients. Moreover, very few studies reported the relationship between p-ATM expression and patient survival \[[@pone.0134678.ref023]\]. Since ATM is a kinase, and its activation by phosphorylation at ser-1981 position allows it to associate itself with other DNA repair proteins as well as its down stream targets, analyzing p-ATM expression in patients could yield more accurate results \[[@pone.0134678.ref001], [@pone.0134678.ref003], [@pone.0134678.ref033], [@pone.0134678.ref040]\]. Accordingly, our findings illustrate an association between p-ATM expression, melanoma progression, and patient survival. ATM has important functions in DNA repair and maintenance of genomic integrity and understandably, loss of ATM could be associated with initiation and cancer progression \[[@pone.0134678.ref049]\]. On the other hand, ATM mediated regulation of signalling cascades could also drive cancer progression \[[@pone.0134678.ref049]\]. Our results showing that both loss of, and gain in, p-ATM expression are associated with melanoma progression points to the importance of tight regulation of cellular ATM levels. Strikingly, loss of p-ATM was seen to be more obviously associated with early stages of melanoma progression (stage I to stage II), and with tumor thickness, suggests a correlation between p-ATM expression and tumor growth. Our results are consistent with the reports from studies on tissue samples from pancreatic and gastric cancer patients, which showed that loss of ATM expression was associated with tumor progression \[[@pone.0134678.ref019]--[@pone.0134678.ref020], [@pone.0134678.ref047]\]. Previously, strong ATM expression was reported in nodular metastatic melanoma patients and our data showing a correlation between strong p-ATM expression and metastatic melanoma supports the hypothesis that ATM is involved in melanoma metastasis \[[@pone.0134678.ref024]\].

Along these lines, patients with strong p-ATM expression had the worst 5-year survival, patients with weak to moderate expression had the best survival, whereas patients with negative expression had intermediate survival. Understandably, a high level of activated p-ATM is associated with transformation of melanoma into a more aggressive and malignant phenotype and thereby associated with poor prognosis. Similarly, patients with negative expression of p-ATM might have had larger tumors, faster melanoma progression and consequently worse prognosis. The finding that patients with strong p-ATM had significantly worse survival compared to patients with negative to moderate expression, points to the oncogenic nature of ATM. The independence of strong p-ATM expression in predicting the survival outcome of patients in multivariate Cox regression analysis further supports its oncogenic nature. The therapeutic potential of ATM inhibition is currently being explored by researchers and ATM inhibitors have shown promise in preclinical xenograft models \[[@pone.0134678.ref050]--[@pone.0134678.ref052]\]. Our multivariate analysis data is also encouraging for additional research on the use of ATM inhibitors for treating melanoma. However, our results from 10-year survival analysis, showing close overlap of survival curves of patients with negative and strong p-ATM expression, points to the possible disadvantages of complete inhibition of the kinase.

Induction of apoptosis by DNA damaging agents like etoposide and cisplatin has been shown previously to cause caspase-3 mediated cleavage of ATM protein \[[@pone.0134678.ref053]--[@pone.0134678.ref054]\]. The cleaved ATM protein lacked the kinase activity against p53 but retained the DNA binding ability \[[@pone.0134678.ref053]--[@pone.0134678.ref054]\]. Our results on association between treatment with DNA damaging agents, chemoresistance and p-ATM expression indicates the critical role of ATM in cell survival and encourages further research on cleaved products of ATM.

Although our database was relatively large and we had information on most of the clinicopathologic characteristics of patients, due to the retrospective nature of the study we could not include all the recognized prognostic factors in our analysis. More studies with more patient information could conclusively determine the usefulness of ATM inhibition in the treatment of melanoma. Nevertheless, our study demonstrates association between p-ATM expression, melanoma progression and patient survival, and encourages further research. In summary, nuclear p-ATM expression has prognostic significance and may be a potential biomarker and molecular target for melanoma treatment.
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